The U.S. Food and Drug Administration has granted orphan drug designation for SteroTherapeutics’ ST-002 in the treatment of nonalcoholic fatty liver disease, nonalcoholic steatosis and hyperglycemia in patients with Cushing’s syndrome.   “We are pursuing a drug that has a very real potential to become the optimal agent of choice and a standard of care for these Cushing’s patients,” said Manohar Katakam Ph. D., chief executive officer of SteroTherapeutics. “Our clinical trial will t...